Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pembrolizumab + Pemetrexed Disodium |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, PMBL, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-positive NSCLC, esophageal SCC, cervical cancer, and TNBC, in combination with platnum-based chemo in NSCLC, with pemetrexed and platinum in pleural mesothelioma and non-sNSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in sNSCLC, with axitinib or lenvatinib in RCC, with lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemo for esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemo for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, in combination with fluoropyrimidine- and platinum-containing chemo for HER2-negative gastric or GEJ adenocarcinoma, in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-positive (CPS>=1) cervical cancer, in combination with gemcitabine and cisplatin for biliary tract cancer, in combination with chemoradiation for cervical cancer, and in combination with carboplatin and paclitaxel for endometrial carcinoma (FDA.gov). |
Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04547504 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE) | Active, not recruiting | FRA | 0 |
NCT03793179 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 1 |
NCT06364917 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | Not yet recruiting | USA | 0 |
NCT04220892 | Phase I | Abemaciclib + Pembrolizumab Pembrolizumab + Pemetrexed Disodium | Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | Withdrawn | USA | 0 |
NCT06311721 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab ABP 234 + Cisplatin + Pemetrexed Disodium ABP 234 + Carboplatin + Pemetrexed Disodium ABP 234 + Pemetrexed Disodium | A Study to Compare ABP 234 and Keytruda (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Recruiting | USA | POL | ITA | ESP | 5 |
NCT04622007 | Phase II | Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium + Tomivosertib Pembrolizumab Pembrolizumab + Tomivosertib | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART) | Active, not recruiting | USA | AUS | 1 |
NCT03664024 | Phase II | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) | Completed | USA | ISR | HUN | ESP | CAN | 0 |
NCT04895735 | Phase II | Pembrolizumab + Pemetrexed Disodium | Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | Recruiting | USA | 0 |
NCT04964960 | Phase II | Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab | Pembro+Chemo in Brain Mets | Terminated | USA | 0 |
NCT03083808 | Phase II | Gemcitabine + Pembrolizumab Docetaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium | Phase II Trial of Continuation Therapy in Advanced NSCLC | Completed | USA | 0 |
NCT05775289 | Phase II | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + RO7247669 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Pemetrexed Disodium + RO7247669 Carboplatin + Pemetrexed Disodium + RO7247669 RO7247669 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ITA | FRA | ESP | DEU | BRA | BEL | AUS | 2 |
NCT05692999 | Phase III | Pembrolizumab + Pemetrexed Disodium | Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (Pulse) | Recruiting | FRA | 0 |
NCT06627647 | Phase III | AZD2936 + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Not yet recruiting | USA | TUR | HUN | GBR | ESP | DEU | CAN | BRA | BEL | ARG | 7 |
NCT03976323 | Phase III | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Olaparib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | Active, not recruiting | USA | TUR | ROU | POL | NZL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 6 |
NCT04619797 | Phase II | Atezolizumab + Pemetrexed Disodium + Tiragolumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06) | Active, not recruiting | USA | TUR | POL | NZL | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | 7 |
NCT04297605 | Phase I | Pembrolizumab + Pemetrexed Disodium Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 | Recruiting | USA | 0 |
NCT03626922 | Phase I | Folic Acid Cyanocobalamin Oxaliplatin + Pembrolizumab + Pemetrexed Disodium Dexamethasone Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | Unknown status | USA | 0 |
NCT05255302 | Phase II | Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL) | Recruiting | FRA | 0 |